PureTech Health’s (PRTC) Buy Rating Reaffirmed at Liberum Capital

Liberum Capital reaffirmed their buy rating on shares of PureTech Health (LON:PRTC) in a report released on Thursday, ThisIsMoney.Co.Uk reports.

PRTC has been the topic of several other research reports. Jefferies Financial Group reiterated a buy rating and set a GBX 255 ($3.33) price objective on shares of PureTech Health in a research note on Wednesday, April 17th. Peel Hunt reiterated a buy rating on shares of PureTech Health in a research note on Thursday, January 31st.

PRTC traded up GBX 8 ($0.10) on Thursday, hitting GBX 199 ($2.60). 17,688 shares of the company’s stock were exchanged, compared to its average volume of 71,917. The firm has a market cap of $562.16 million and a price-to-earnings ratio of -12.44. PureTech Health has a twelve month low of GBX 135 ($1.76) and a twelve month high of GBX 215 ($2.81). The company has a quick ratio of 0.95, a current ratio of 0.98 and a debt-to-equity ratio of 7.19.

PureTech Health Company Profile

PureTech Health plc, a clinical-stage biopharma company, focuses on developing medicines for diseases caused by dysfunctions in the nervous, gastrointestinal, and immune systems. The company is developing a microbiome immune system drug-discovery platform and drug candidates for immune-mediated diseases; and products to induce weight loss and enhance glycaemic control through an orally administered capsule.

Featured Article: Why investors pay attention to retained earnings

Receive News & Ratings for PureTech Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PureTech Health and related companies with MarketBeat.com's FREE daily email newsletter.